Infection prophylaxis
Conditions
Brief summary
Population pharmacokinetic parameters and inter-individual variability: distribution volume, total clearance, intercompartmental clearance (plasma to mediastinum)
Detailed description
Monte Carlo simulations performed using the model with SimulX (version 2024R1) and R (version 4.4.2) software, Data collected during the month following probe removal: Clinical progression: survival or death, post-operative mediastinitis, other bacterial infections, MIC of the bacteria if measured; Antibiotics received; Inflammation markers and progression: CRP.
Interventions
DRUGCEFAZOLIN
Sponsors
Assistance Publique Hopitaux De Paris
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Population pharmacokinetic parameters and inter-individual variability: distribution volume, total clearance, intercompartmental clearance (plasma to mediastinum) | — |
Secondary
| Measure | Time frame |
|---|---|
| Monte Carlo simulations performed using the model with SimulX (version 2024R1) and R (version 4.4.2) software, Data collected during the month following probe removal: Clinical progression: survival or death, post-operative mediastinitis, other bacterial infections, MIC of the bacteria if measured; Antibiotics received; Inflammation markers and progression: CRP. | — |
Outcome results
None listed